Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

byiShook Opinion
Sep 10, 2024 - 10:50

Share

Viridian Therapeutics stock jumped Tuesday after unveiling promising results for its Amgen-rivaling eye disease treatment. The post Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival appeared first on Investor's Business Daily.

Viridian Therapeutics stock jumped Tuesday after unveiling promising results for its Amgen-rivaling eye disease treatment.

The post Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival appeared first on Investor's Business Daily.